Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers
about
Strategies and challenges in eliciting immunity to melanoma.WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase.Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation.The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xLTumor-associated antigens in breast cancer.The role of peptide and DNA vaccines in myeloid leukemia immunotherapyAdult human sarcomas. I. Basic science.T-cell receptor gene therapy for cancer: the progress to date and future objectives.Immunotherapy for myeloid leukemias: current status and future directions.WT1 expression is increased in primary fibroblasts derived from Dupuytren's disease tissues.Development of cellular and humoral response against WT1 protein vaccination in mice.High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organ.Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations.WT1 expression in endocrine mucin-producing sweat gland carcinoma: a study of 13 cases.WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval.Cross-sectional monitoring of Wilms' tumor gene 1 (WT1) expression in Iranian patients with acute lymphoblastic leukemia at diagnosis, relapse and remission.
P2860
Q30435893-7452E66C-EE10-42C7-96A8-5762D73FF28BQ33814519-E5ACA1FF-32B3-40C8-BE31-FA80EDDC1691Q35553621-3A0FD3B9-1264-48F4-AF47-655D436DE9B8Q36294675-9ACD7EBD-09F1-43E2-8CBF-8EDA83F6348EQ36449259-3E80FA14-AB60-44D0-9D35-70FC52D255C2Q36608571-7F2C5A50-5DFB-40E3-93C1-AB6680A3A63AQ36691805-F5800500-B477-4BDB-B3F2-EDDDD2318810Q36909378-F02DB9D1-5173-46CA-BBD2-7DF61E90E282Q37194498-9C648640-56E1-469E-BF16-9900B487F522Q42147687-D75ACCE8-4B0D-4742-83E6-6875AE04CE13Q42386145-ADB8B51F-58AB-4412-B4EB-7FAD2B0EF4DDQ51887293-62CC3625-8F44-45B8-B4C5-FB046E9012FAQ52938002-58DB89BC-ABE4-40F8-8F69-D5830FBEB226Q53020264-8B6C1D4A-3A40-406B-B8F1-9E6819B7B7B6Q53345813-3D6F3816-5157-4494-864F-275A3AD213F3Q54549001-A8373843-3E60-4605-BA9B-1F64F11EC228
P2860
Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers
description
2006 nî lūn-bûn
@nan
2006 թուականին հրատարակուած գիտական յօդուած
@hyw
2006 թվականին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Development of WT1 peptide can ...... malignancies and solid cancers
@ast
Development of WT1 peptide can ...... malignancies and solid cancers
@en
Development of WT1 peptide can ...... malignancies and solid cancers
@nl
type
label
Development of WT1 peptide can ...... malignancies and solid cancers
@ast
Development of WT1 peptide can ...... malignancies and solid cancers
@en
Development of WT1 peptide can ...... malignancies and solid cancers
@nl
prefLabel
Development of WT1 peptide can ...... malignancies and solid cancers
@ast
Development of WT1 peptide can ...... malignancies and solid cancers
@en
Development of WT1 peptide can ...... malignancies and solid cancers
@nl
P2093
P1476
Development of WT1 peptide can ...... malignancies and solid cancers
@en
P2093
H Nakajima
H Sugiyama
M Kawakami
O A Elisseeva
P304
P356
10.2174/092986706777935104
P407
P577
2006-01-01T00:00:00Z